UMB Bank N A MO Has $14,872,000 Stake in Bristol-Myers Squibb Co. (BMY)
UMB Bank N A MO lowered its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 2.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 202,199 shares of the biopharmaceutical company’s stock after selling 5,794 shares during the period. UMB Bank N A MO’s holdings in Bristol-Myers Squibb were worth $14,872,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of Montreal Can acquired a new position in Bristol-Myers Squibb during the second quarter valued at $154,732,000. IBM Retirement Fund boosted its position in Bristol-Myers Squibb by 1.1% in the second quarter. IBM Retirement Fund now owns 219,448 shares of the biopharmaceutical company’s stock valued at $16,627,000 after buying an additional 2,421 shares in the last quarter. HL Financial Services LLC boosted its position in Bristol-Myers Squibb by 0.8% in the second quarter. HL Financial Services LLC now owns 360,221 shares of the biopharmaceutical company’s stock valued at $26,494,000 after buying an additional 2,901 shares in the last quarter. PGGM Investments boosted its position in Bristol-Myers Squibb by 1.3% in the second quarter. PGGM Investments now owns 1,321,858 shares of the biopharmaceutical company’s stock valued at $97,223,000 after buying an additional 17,200 shares in the last quarter. Finally, Howard Capital Management boosted its position in Bristol-Myers Squibb by 0.7% in the second quarter. Howard Capital Management now owns 153,499 shares of the biopharmaceutical company’s stock valued at $11,290,000 after buying an additional 1,068 shares in the last quarter. 72.88% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.94% during mid-day trading on Friday, hitting $49.77. The company had a trading volume of 13,848,384 shares. The firm’s 50 day moving average is $55.09 and its 200 day moving average is $66.31. The company has a market capitalization of $83.16 billion, a price-to-earnings ratio of 29.11 and a beta of 0.74. Bristol-Myers Squibb Co. has a 52 week low of $49.12 and a 52 week high of $77.12.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.66 by $0.03. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The business had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.60 billion. During the same period last year, the business posted $0.53 EPS. The company’s revenue was up 17.2% compared to the same quarter last year. On average, equities research analysts predict that Bristol-Myers Squibb Co. will post $2.63 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be paid a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 annualized dividend and a yield of 3.05%. Bristol-Myers Squibb’s dividend payout ratio is 87.36%.
BMY has been the topic of several research analyst reports. Goldman Sachs Group Inc. cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $75.00 price objective on the stock. in a research report on Thursday. Barclays PLC reissued an “equal weight” rating on shares of Bristol-Myers Squibb in a research report on Wednesday. Morgan Stanley reissued a “hold” rating on shares of Bristol-Myers Squibb in a research report on Thursday, August 25th. Deutsche Bank AG cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, August 5th. Finally, SunTrust Banks Inc. reissued a “hold” rating and issued a $62.00 price objective (down previously from $68.00) on shares of Bristol-Myers Squibb in a research report on Monday, October 10th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $69.31.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 23,200 shares of the stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $59.17, for a total transaction of $1,372,744.00. Following the sale, the director now directly owns 364,999 shares in the company, valued at approximately $21,596,990.83. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.24% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.